GeoVax Labs Responds to HHS's Termination of mRNA Vaccine Contracts

Strategic Insights -

GeoVax Labs, a clinical-stage biotechnology company, has issued a statement in response to the U.S. Department of Health and Human Services' (HHS) decision to terminate nearly $500 million in BARDA-funded mRNA vaccine development contracts. This action reflects a policy shift, underscored by HHS Secretary Kennedy's remarks on the limitations of mRNA vaccines. GeoVax's vaccine candidates, including GEO-CM04S1 for COVID-19, are designed to induce immunity using multiple antigens, offering broader and more durable protection even as the virus mutates.

Key Takeaways:

  • GeoVax's GEO-CM04S1 vaccine candidate has demonstrated robust and durable antibody and T-cell immunity in Phase 2 trials, outperforming mRNA comparator arms in clinical studies.
  • GeoVax's MVA-based vaccine platform has a validated safety profile, with a track record of evidence-backed safety for immunocompromised, pediatric, and pregnant populations.
  • GeoVax's platform is positioned to support scalable, decentralized U.S. vaccine manufacturing, providing faster production, higher yield at a reduced cost, and a strategic advantage for public health resilience.
  • GeoVax's vaccine candidates offer broad infectious-disease pipeline coverage, targeting hemorrhagic fever viruses, Zika, and Mpox/Smallpox, aligning with HHS, NIH, FDA, and WHO priorities for pandemic preparedness and biodefense.
  • GeoVax urges HHS to proactively support robust, evidence-backed alternatives, including multi-antigen platforms like MVA, as part of a diversified, resilient biomedical countermeasure arsenal.

Statistics:

  • $500 million: the amount of funding terminated by HHS for mRNA vaccine development contracts.
  • 3: the number of Phase 2 clinical trials for GeoVax's COVID-19 vaccine candidate.
  • 100%: the demonstrated efficacy of GEO-CM04S1 in inducing immune responses across variants, from the original Wuhan strain to Omicron, in immunocompromised patients.
  • 1: the number of MVA-based vaccines in development for Mpox and smallpox, with plans for a Phase 3 clinical evaluation.

Sources:

  • GeoVax Labs, Inc.
  • U.S. Department of Health and Human Services
  • National Institute of Health (NIH)
  • Food and Drug Administration (FDA)
  • World Health Organization (WHO)